Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Agios Pharmaceuticals Inc AGIO

Healthcare Biotechnology
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined... see more

Recent & Breaking News (NDAQ:AGIO)

Agios Appoints Steve Hoerter as Chief Commercial Officer

GlobeNewswire February 8, 2016

Agios to Present at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10

GlobeNewswire February 3, 2016

Agios Outlines Key 2016 Goals and Priorities

GlobeNewswire January 11, 2016

Agios to Present at the 34th Annual J.P. Morgan Healthcare Conference on Monday, January 11

GlobeNewswire January 4, 2016

Agios Announces Initiation of Phase 1b Frontline Trial of AG-221 or AG-120 in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients

GlobeNewswire December 18, 2015

Agios Announces Data from Ongoing Phase 1/2 Trial of AG-221 Showing Durable Responses in Patients with Advanced Hematologic Malignancies

GlobeNewswire December 6, 2015

Agios Announces Data from Ongoing Phase 1 Trial of AG-120 Showing Durable Responses in Patients with Advanced Hematologic Malignancies

GlobeNewswire December 5, 2015

Agios Announces Data from Dose-Escalation Phase 1 Study of AG-120 in Patients with IDH1 Mutant Positive Advanced Solid Tumors

GlobeNewswire November 8, 2015

Agios to Present New Data From Lead Programs at the 2015 ASH Annual Meeting

GlobeNewswire November 5, 2015

Agios Reports Third Quarter 2015 Financial Results

GlobeNewswire November 5, 2015

Agios to Present at Credit Suisse 24th Annual Healthcare Conference on Tuesday, November 10

GlobeNewswire November 3, 2015

Agios to Webcast Conference Call of Third Quarter 2015 Financial Results on November 5, 2015

GlobeNewswire October 29, 2015

Agios to Present Clinical Data from Ongoing AG-120 Phase 1 Trial in Advanced Solid Tumors at AACR-NCI-EORTC

GlobeNewswire October 26, 2015

Agios Outlines Key Clinical Development & Research Strategies

GlobeNewswire October 16, 2015

Agios to Webcast R&D Day on October 16, 2015

GlobeNewswire October 8, 2015

Agios to Present at Leerink Partners Rare Disease Roundtable

GlobeNewswire September 23, 2015

Agios Reports Second Quarter 2015 Financial Results and Provides Updates on Clinical Development Progress

GlobeNewswire August 6, 2015

Agios to Present at Canaccord Genuity 35th Annual Growth Conference Wednesday, August 12, 2015

GlobeNewswire August 5, 2015

Agios to Webcast Conference Call of Second Quarter 2015 Financial Results on August 6, 2015

GlobeNewswire July 30, 2015

Agios Announces First Patient Dosed with AG-881 in Phase 1 Study in Patients with Advanced Solid Tumors with an IDH Mutation

GlobeNewswire June 24, 2015